(b)(4).There was no reported device malfunction and the product was not returned as the scaffold remains in the anatomy.A review of the lot history record and complaint history of the reported lot could not be conducted because the lot number was not provided.The reported patient effects of angina, myocardial infarction and restenosis, as listed in the bioresorbable vascular scaffold (bvs) system, absorb, instructions for use are known adverse events associated with the use of a coronary scaffold in native coronary arteries.Based on the case information, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to design, manufacture or labeling of the device.The absorb device is currently not commercially available in the u.S; however, it is similar to a device sold in the us.
|
It was reported that the procedure was to treat the proximal right coronary artery.On (b)(6) 2014, a 3.0 x 18 mm absorb scaffold was implanted; however, on (b)(6) 2018, the patient experienced angina and optical coherence tomography (oct) imaging revealed that there was in-stent restenosis (isr).Additionally, a myocardial infarction was diagnosed.This was treated with a 3.0 x 23 mm xience alpine stent.There was no adverse patient sequela reported.No additional information was provided.
|